Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease
Vittorio, Serena (Università degli Studi di Messina Viale Palatucci. Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali)
Adornato, Ilenia (Università degli Studi di Messina Viale Palatucci. Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali)
Gitto, Rosaria (Università degli Studi di Messina Viale Palatucci. Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali)
Peña Díaz, Samuel (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Ventura, Salvador (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
De Luca, Laura (Università degli Studi di Messina Viale Palatucci. Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali)
Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular

Data:	2020
Resum:	Parkinson's disease is one of the most common neurodegenerative disorders in elderly age. One of the mechanisms involved in the neurodegeneration appears related to the aggregation of the presynaptic protein alpha synuclein (α-syn) into toxic oligomers and fibrils. To date, no highly effective treatment is currently available; therefore, there is an increasing interest in the search of new therapeutic tools. The modulation of α-syn aggregation represents an emergent and promising disease-modifying strategy for reducing or blocking the neurodegenerative process. Herein, by combining in silico and in vitro screenings we initially identified 3-(cinnamylsulfanyl)-5-(4-pyridinyl)-1,2,4-triazol-4-amine (3) as α-syn aggregation inhibitor that was then considered a promising hit for the further design of a new series of small molecules. Therefore, we rationally designed new hit-derivatives that were synthesised and evaluated by biological assays. Lastly, the binding mode of the newer inhibitors was predicted by docking studies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Parkinson's disease ; Alphasynuclein ; Ligand-based pharmacophore ; Aggregation inhibitors ; Docking studies
Publicat a:	Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 35, Issue 1 (September 2020) , p. 1727-1735, ISSN 1475-6374

DOI: 10.1080/14756366.2020.1816999
PMID: 32924648

10 p, 3.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Biotecnologia i de Biomedicina (IBB)
Articles > Articles de recerca
Articles > Articles publicats